long intergenic non-protein coding RNA 2683Genealiases: []
Q-omics provides the consensus-scored LINC02683 profile across patient tissues and cancer cell-line models. LINC02683 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LINC02683 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, LINC02683 RNA expression shows 9,938 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KICH, LUAD, and LIHC as cancer lineages where LINC02683 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02683 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02683 survival associations across molecular data types. LINC02683 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02683 RNA expression–survival associations across cancer types. High LINC02683 expression shows unfavorable associations in KICH, UCS, COAD and DLBC, but favorable associations in UVM and LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LINC02683 RNA expression.
This table summarizes LINC02683 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02683. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02683 shows lower tumor expression in KICH and higher tumor expression in LUAD, KIRC, KIRP, THCA and PAAD. The LUAD box plot shows higher LINC02683 RNA expression in tumor versus normal tissue (log2 FC = +0.428, t-test p < 0.001).
This table shows molecular features associated with LINC02683 in patient tissues and cancer cell lines. In patient samples, LINC02683 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
